Brigham and Women’s Hospital (BWH) has been the site of important medical and surgical innovations in lung and respiratory health care for well over a century—stretching back to when BWH was known as the Boston Lying-In Hospital and the Peter Bent Brigham Hospital
Anesthesia was administered in childbirth for the first time in 1847 at the Boston Lying-In Hospital. In 1929, the Peter Bent Brigham Hospital introduced the world to the Drinker respirator (or iron lung), which successfully saved a young polio patient’s life. In the early 1990s, a team of surgeons participated in the first wave of successful lung, heart-lung and triple organ transplants at BWH. Thoracic surgeons here were also among the first to develop minimally invasive lung surgery and, more recently, image-guided thoracic surgery (iVATS).
These milestones had their infancy in the research laboratories of BWH where physician-scientists continue to discover and test respiratory treatments and cures, including landmark studies in chronic obstructive pulmonary disease (COPD) and asthma. It was only fitting that clinical and research expertise for lung disease merged at BWH in 2015. The Lung Center and its affiliated Lung Research Center launched, heralding a strong connection between respiratory specialists and sub-specialists throughout BWH in clinical care and innovation and marking a new era in lung health for adults with respiratory disease.
Brigham and Women’s Hospital has been the site of important medical and surgical innovations in lung and respiratory health care for well over a century.
Physician-researchers from the International Mesothelioma Program at Brigham and Women’s Hospital, one of the largest mesothelioma treatment and research programs in the world, are studying the disease to better understand its biology and develop treatment strategies to target its vulnerabilities.
Elliot Israel, MD, director of the Asthma Research Center in the Pulmonary and Critical Care Medicine Division at Brigham and Women’s Hospital, is investigating a novel strategy that presents an alternative to the daily use of an inhaled corticosteroid (ICS) to prevent asthma attacks.